UNITY Biotechnology Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema
About The Event
Join us for a virtual program update with UNITY Biotechnology, featuring retinal expert and senior clinical advisor Robert B. Bhisitkul, M.D., Ph.D. (University of California San Francisco School of Medicine), to discuss UNITY’s lead program evaluating the safety and efficacy of UBX1325 in patients with diabetic macular edema (DME).
The UNITY leadership team will present data from BEHOLD, the Phase 2 clinical trial of UBX1325 in patients with DME. UBX1325 is a potent small molecule inhibitor of Bcl-xL, a member of the Bcl-2 family of apoptosis regulating proteins.
A live question and answer session will follow the formal presentations.